Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > FAQs about November 2023’s NICE recommendations on hybrid closed loop
The final appraisal document has been issued to stakeholders for appeal. NICE anticipate publishing final guidance in December 2023. Once published, it is expected to take five years to get everyone who is eligible onto HCL technology.
NICE recommends HCL as a treatment option for the following groups of people with type 1 diabetes:
Adults with an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling hypoglycaemia, despite best possible management with at least one of the following: an insulin pump OR CGM OR flash. Disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life.
The phrase ‘best possible management’ and the list of devices is not intended to be something that excludes people but rather something that shows clinicians the pathway towards best care. If you’re not on one of those three devices, rather than your clinic saying you don’t meet the criteria for HCL, they should offer you a pump, CGM or flash as the next step in improving your glucose management.
All children and young people, whatever their HbA1c.
Women who are pregnant or planning a pregnancy, whatever their HbA1c.
These recommendations are not intended to affect use of HCL systems that were started on the NHS before this guidance was published. People using HCL systems outside of these recommendations may continue to do so.
NICE’s decision is based on a range of research, evidence and health economic data. It applies to over 100,000 people with type 1 diabetes. NICE will review this guidance in the coming years as part of their usual process, and we hope the criteria will be expanded at that time to cover everyone with type 1. We won’t rest until everyone who could benefit from HCL has access free at the point of need across the four nations.
The law normally requires integrated care boards (ICBs), NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within three months of its date of publication.
The normal timescale has been extended to five years for this technology because of the following considerations:
For context, NICE technology appraisal 151 about insulin pump therapy was updated in 2008, and it has taken 15 years to get 26,000 adults in England on to pumps and there are still thousands of eligible people who are not using pumps. In order to get well over 100,000 people onto HCL within five years, it will take careful planning and big changes in the way clinics train new users.
The five-year roll out plan will be a guide, but local clinic teams can use their clinical judgement to decide if individual people need to access HCL sooner.
Speak to your Diabetes Healthcare Team at your next appointment to find out about access and their timescales for rolling out the technology.
This is NICE’s decision based on a range of research, evidence and health economic data. We understand the frustration of those who don’t qualify. We expect the criteria to be reviewed in coming years as part of the normal NICE process, and we won’t rest until everyone who could benefit from HCL has access free at the point of need across the four nations.
The recommendations cover England and Wales. Scotland has already approved HCL under its own recommendations. We will work to open up access to type 1 diabetes technology and HCL in Northern Ireland.
NHS Scotland has recommended that hybrid closed loop systems should be pro-actively discussed with all patients with type 1, particularly those who have:
It also recommended that people already using both a CGM and an insulin pump should be offered a hybrid closed loop system, but if people are managing well with how they already manage their type 1, they should stay on that care plan.
Read the recommendations in full for more detail.
There are several HCL systems available that work with a variety of pumps and CGMs. Talk to your Diabetes Healthcare Team about what might be available to you.
We don’t know at the moment. Your first conversation should be with your Diabetes Healthcare Team, who will be able to advise you on timescales. Once the roll out plan starts it will take five years to train all those who are eligible.
It depends on whether you meet the access criteria. The best thing to do is to speak to your Diabetes Healthcare Team. And remember, once the roll out plan starts, it will take five years to cover all those who are eligible.
We hope so. NICE reviews all their recommendations. We expect the outcomes from the early adopters of this technology will influence the criteria when it is reviewed in the future. We won’t rest until everyone who would benefit from this technology is offered it free at the point of need.
Yes! Most people who are eligible will be currently using insulin pens, not a pump.
NICE technology appraisals, unlike NICE clinical guidance, puts an obligation on the ICB to fund this treatment for those who meet criteria and have clinical support. The NICE technology appraisal about insulin pumps was updated in 2008, and it has taken 15 years to get 26,000 adults in England on to pumps. We now want to get well over 100,000 people onto HCL within five years.
The Diabetes Technology Network is encouraging clinics to establish new ways to train and onboard new HCL users so that they can be on HCL in a reasonable timescale. It’s unlikely to be a step up of current practice, more likely to be a radically different way of getting large numbers of users trained. So, if you are on a waiting list for a pump don’t feel defeated – change is coming. We will update this page when we have more information.
NICE technology appraisals set out the legal obligations for the ICB, and guidance for clinical staff. There are no legal obligations on your clinical team though, they will use their clinical judgement. If you think you meet the criteria but are being declined access, contact us through our contact form.
The NHS is legally obliged to fund and resource medicines and treatments recommended by NICE’s technology appraisals.
The NHS Constitution states that patients have the right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.
When NICE recommends a treatment ‘as an option’, every ICB must make sure it is available. This means that, if a patient has a disease or condition and the doctor responsible for their care thinks that the technology is the right treatment, it should be available for use, in line with NICE’s recommendations.
If your Diabetes Healthcare Team is unfamiliar with HCL you can ask your GP to refer you to another clinic. As long as you have a good reason, your GP should agree. Not being offered the treatment you consider you need is a good reason. You do not need to ask your current clinic to refer you, it has to come from your GP. And remember, once the roll out plan starts, it will take five years to cover all those who are eligible.
NICE considered other types of diabetes that could benefit from HCL systems, including type 3c diabetes (in which the pancreas is damaged) and cystic fibrosis-related diabetes. NICE noted that whilst there is no evidence on the use of HCL systems for these conditions, the clinical benefits were likely to be similar to the clinical benefits for people with type 1. Therefore, NICE concluded that HCL systems could be useful in these groups but this was outside the scope for this document.
Take a look at our website about hybrid closed loop systems.
You can find out more about what the experts think about different devices on the DTN network.
Read the NICE final appraisal document for reference.
Contact us by using our contact form.
Hybrid closed loop technology – also known as the artificial pancreas – automates many of the decisions that you have to make on a daily basis when you have type 1 diabetes.
Find out more about what the experts think about different devices on the DTN network website.
Read the NICE final draft guidance on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.